When Will Malaria Meds Stop Working In Africa?

What the report says

Forbes reported that scientists and malaria policy specialists are warning African health systems to treat emerging resistance to artemisinin-based malaria medicines as an urgent threat, even though artemisinin-based combination therapies, or ACTs, still work for now. The concern is that treatments many patients rely on could become less effective as resistant parasites spread, especially in places with high malaria burdens.

The article says artemisinin resistance first appeared in Southeast Asia in the 2000s and was largely contained through elimination campaigns, patient management and changes in drug combinations. Experts quoted by Forbes said Africa presents a much larger challenge because resistant parasites are appearing amid hundreds of millions of malaria cases annually. Maciej Boni, an epidemiologist at Temple University, identified Uganda as a major concern, while Forbes said partial resistance has also been confirmed in Eritrea, Rwanda and Tanzania and is suspected elsewhere.

A central issue is uneven surveillance. Some countries, including Tanzania and Burkina Faso, were described as having stronger molecular monitoring systems, but other areas have major gaps. Issiaka Soulama of Burkina Faso’s National Center for Research and Training on Malaria said his team lacks data from many sentinel sites and is working with a two-year lag. Michael Audu, an independent malaria policy researcher in Nigeria, called for tracking both drug performance and early genetic warning signs, particularly mutations in the Kelch13 gene.

Forbes also noted that new antimalarial options, including GanLum, may offer alternatives, but specialists cautioned that new medicines alone will not solve the problem if surveillance, treatment systems and funding remain weak. The broader implication is that resistance could quietly expand before health authorities detect widespread treatment failure.